Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.58 |
| ▸ | CDK2 | P24941 | 7/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13308741 | 0.93 | GSK3B (0.57) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13885077 | 0.90 | CDK2 (0.57) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL11931062 | 0.89 | GSK3B (0.61) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL11931064 | 0.89 | GSK3B (0.55) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13309248 | 0.89 | GSK3B (0.54) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13308745 | 0.89 | GSK3B (0.54) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL14528951 | 0.89 | KDM4E (0.45) | GSK3BCDK2KDM4ETP53POLB | |
| SCHEMBL11931063 | 0.88 | GSK3B (0.54) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13885070 | 0.88 | GSK3B (0.60) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13885123 | 0.87 | GSK3B (0.54) | GSK3BCDK2CCNE1CHEK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1934224-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-7514442-B2 | Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514442-B2 | Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1534712-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007044441-A2 | USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044420-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7205308-B2 | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205308-B2 | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | GSK3B 334/4885CDK2 64/4885CCNE1 895/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | GSK3B 334/4885CDK2 64/4885CCNE1 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.